Meeting
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
Authors
Joshua Brody
Icahn School of Medicine at Mount Sinai, New York, NY
Joshua Brody , Bjorn E. Wahlin , Tycel Jovelle Phillips , Régis Costello , Pieternella Lugtenburg , Raul Cordoba , Liwei Wang , Jun Wu , Brian Elliott , Aqeel Abbas , Judit Jørgensen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT04663347
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7527)
DOI
10.1200/JCO.2022.40.16_suppl.7527
Abstract #
7527
Poster Bd #
181
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.
First Author: Pau Abrisqueta
Poster
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Catherine Thieblemont
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg